Click to enlarge
Buy Perjeta (Pertuzumab) $1,470.00
Back to products
Buy Vegzelma (Bevacizumab-adcd) $375.00 – $1,125.00

Buy Tecentriq (Atezolizumab)

$3,604.50

Tecentriq (atezolizumab) is a medication used for the treatment of locally advanced or metastatic urothelial carcinoma, for the treatment of metastatic non-small cell lung cancer (NSCLC), and for the treatment of advanced triple negative breast cancer (TNBC).

Clear
Compare
Add to wishlist
SKU: N/A Category:
Description

What is Tecentriq (atezolizumab) for?

Tecentriq (atezolizumab) is a programmed death-ligand 1 (PD-L1) blocking antibody indicated for the treatment of patients with:

  • locally advanced or metastatic urothelial carcinoma who have either; disease progression during or following platinum-containing chemotherapy, or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy or are not eligible for cisplatin chemotherapy
  • metastatic non-small cell lung cancer (NSCLC) whose disease progressed during or following platinum-containing chemotherapy.
  • plus nab-paclitaxel (chemotherapy) for unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumours have PD-L1 expressioN.

How does Tecentriq (atezolizumab) work?

Tecentriq (atezolizumab) belongs to a class of immunotherapy drugs known as checkpoint inhibitors.

The drug prevents a protein called PD-L1 that is found on some tumour cells from binding to another protein, PD-1, on immune cells. The binding of these “checkpoint” proteins suppresses the immune response. Tecentriq (atezolizumab) is a monoclonal antibody that binds to PD-L1 and blocks its interactions with both PD-1 and B7.1 receptors. By blocking this interaction, checkpoint inhibitors “release the brakes” on the immune system, allowing immune cells to attack tumours.

Is Tecentriq (atezolizumab) approved?

Tecentriq (atezolizumab) was approved by:

  • Food and Drugs Administration (FDA) (USA)
    • on May 18, 2016, for locally advanced or metastatic urothelial carcinoma, with disease progression on or after prior chemotherapy. On April 17, 2017, the FDA extended the approval to the use of Tecentriq (atezolizumab) as front-line treatment for advanced or metastatic urothelial carcinoma in patients who are not eligible for cisplatin chemotherapy.
    • on October 18, 2016, for metastatic non-small cell lung cancer (NSCLC).
  • Health Canada on April 12, 2017
    • for locally advanced or metastatic urothelial carcinoma, with disease progression on or after prior chemotherapy.
    • for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) in combination with carboplatin and etoposide.
    • for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC) in combination with bevacizumab, paclitaxel and carboplatin.
    • for adult patients with locally advanced or metastatic NSCLC with progression on or after platinum-based chemotherapy.
  • Therapeutic Goods Administration (TGA) (AUS)
    • on July 27, 2017, for metastatic non-small cell lung cancer (NSCLC).
  • European Medicines Agency (EMA) (EU)
    • on September 22, 2017, for locally advanced or metastatic non-small cell cancer (NSCLC) and metastatic urothelial carcinoma (mUC) on patients who have been previously treated with a platinum-based chemotherapy and as front-line treatment for advanced or metastatic urothelial carcinoma in patients who are not eligible for cisplatin chemotherapy.
    • on August 29, 2019, in combination with nab-paclitaxel for advanced TNBC in patients who have not been previously treated with chemotherapy for metastatic disease.
  • Medsafe on February 14, 2019
    • for first-line treatment of patients with metastatic non-squamous NSCLC who do not have tumour EGFR or ALK genomic aberrations.
    • for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy.
    • for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC).
    • for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma.

How do I take Tecentriq (atezolizumab)?

Complete information about Tecentriq (atezolizumab) dosage and administration can be found in the references section.

The recommended therapy consists of:

  • 1200 mg as an intravenous infusion over 60 minutes every 3 weeks.
  • Dilute prior to intravenous infusion.
Complete information about Tecentriq (atezolizumab) dosage and administration can be found in the references section.
Additional information
Quantity

1 vial of 20 mL

Reviews (0)

Reviews

There are no reviews yet.

Be the first to review “Buy Tecentriq (Atezolizumab)”

Your email address will not be published. Required fields are marked *

Shipping & Delivery

Shipping and delivery

All orders will only be dispatched once payment has been confirmed. Please fill in the shipping details and choose the payment method that suits you best.

-Shipping costs
You should always be clearly informed of the total price of your purchase, including delivery and other associated costs.
You must explicitly agree to any additional charges, for example if the merchant offers express delivery or gift wrapping.

-Damaged goods
The merchant is responsible for any damage caused to the product, from dispatch to receipt.
If you have purchased an item that does not conform in appearance or function to the advertised product, you have the right to request that it be repaired, replaced or, if neither of these is possible, refunded.

- Non-delivery
If you have not received the product within 30 days or by the agreed date, you must notify the merchant and allow a reasonable extension of time for delivery.
For example, if the merchant informs you of a one-week delay due to problems with his suppliers, it seems reasonable to allow him this extra week. If the trader still fails to deliver despite the extension, you have the right to terminate the contract and receive a prompt refund.

Related products

Compare
Quick view
Add to wishlist

Buy Darzalex (daratumumab)

$395.00 – $1,185.00
Select options
Darzalex (daratumumab) is a human CD38-directed monoclonal antibody used to treat multiple myeloma

Who is Darzalex (daratumumab) for?

Darzalex (daratumumab) is indicated for patients with:

  • newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant (first-line treatment). For this indication, it is used in combination with bortezomib, melphalan, and prednisone.

  • multiple myeloma who have received at least one prior therapy (second-line treatment). For this indication, it is used in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone.

  • multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor (third-line treatment). For this indication, it is used in combination with pomalidomide and dexamethasone.

  • multiple myeloma who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent (fourth-line treatment). For this indication, it is used as monotherapy.

Compare
Quick view
Add to wishlist

Buy Ibrance (palbociclib)

$1,275.00 – $1,599.00
Select options

What is Ibrance (palbociclib) for?

Palbociclib is indicated for the treatment of postmenopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer as initial endocrine-based therapy for their metastatic disease. It is indicated in combination with an aromatase inhibitor (an hormonal therapy) as initial endocrine based therapy in postmenopausal women or fulvestrant in women with disease progression following endocrine therapy.  

How does Ibrance (palbociclib) work?

 

Palbociclib is an inhibitor of cyclin-dependent kinase (CDK) 4 and 6.

Before a cell can divide, it has to go through four phases. The first phase is a growth phase (G1-phase), the second a synthesis phase (S-phase), the third another growth phase (G2-phase) and the last phase, where the cell divides (M-phase). Cancer cells divide exceedingly fast, passing through these 4 phases rapidly. Palbociclib blocks the progression from the first G1-phase, into the second S-phase. It does this by inhibiting the cyclin-dependent kinases 4 and 6 (CDK4 and CDK6)—two proteins that are involved in entering the S-phase[1].

Compare
Quick view
Add to wishlist

Buy Kadcyla (Trastuzumab Emtansine)

$1,665.00 – $2,669.00
Select options
Kadcyla (trastuzumab emtansine) is a cancer medicine that is used to treat advanced or metastatic HER2-positive breast cancer (cancer that has spread to other parts of the body) in adults who previously received trastuzumab and a taxane.
Compare
Quick view
Add to wishlist

Buy Keytruda (pembrolizumab)

$2,050.00
Select options
Keytruda (pembrolizumab) is a medication used for the treatment of advanced melanoma, metastatic nonsquamous NSCLC, recurrent or metastatic Head and Neck Squamous Cell Carcinoma (HNSCC), recurrent classical Hodgkin Lymphoma (cHL), locally advanced or metastatic urothelial carcinoma, solid tumours having the biomarkers MSI-H or dMMR, recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, triple-negative breast cancer.
Compare
Quick view
Add to wishlist

Buy Opdivo (Nivolumab)

$420.00 – $865.00
Select options
Opdivo (nivolumab) is a medication used for the treatment of certain types of cancer.

What is Opdivo (nivolumab) for?

Opdivo (nivolumab) is indicated for the treatment of patients with:
  • metastatic melanoma as a single agent or in combination with ipilimumab
  • metastatic non-small cell lung cancer (NSCLC) whose cancer progressed on or after chemotherapy
  • advanced renal cell carcinoma who have received prior anti-angiogenic therapy
  • classical Hodgkin lymphoma that has relapsed or progressed after other treatments
  • recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) with disease progression on or within 6 months of receiving platinum-based chemotherapy
  • locally advanced unresectable or metastatic urothelial carcinoma following progression on a platinum-containing therapy
  • microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC) that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan
  • hepatocellular carcinoma in patients who have been previously treated with sorafenib
  • for the adjuvant treatment of completely resected esophageal or gastroesophageal junction (GEJ) cancer with residual pathologic disease in patients who have received neoadjuvant chemoradiotherapy (CRT).
Compare
Quick view
Add to wishlist

Buy Perjeta (Pertuzumab)

$1,470.00
Add to cart
Perjeta (pertuzumab) is a medication used for the treatment of HER2 positive breast cancer in patients with metastatic cancer or as neoadjuvant treatment for patients with locally advanced, inflammatory, or early stage breast cancer as part of a complete treatment regimen for early breast cancer.

What is Perjeta (pertuzumab) for?

Perjeta (pertuzumab) is indicated for the treatment of HER2 positive breast cancer in patients with metastatic cancer or as neoadjuvant treatment for patients with locally advanced, inflammatory, or early stage breast cancer as part of a complete treatment regimen for early breast cancer
Compare
Quick view
Add to wishlist

Buy Vegzelma (Bevacizumab-adcd)

$375.00 – $1,125.00
Select options
Vegzelma (bevacizumab-adcd), a biosimilar to Avastin® (bevacizumab), is a recombinant humanized monoclonal antibody that binds to vascular endothelial growth factor (VEGF), the key driver of vasculogenesis and angiogenesis, and inhibits the binding of VEGF to its receptors Flt-1 (VEGFR-1) and kinase insert domain receptor (VEGFR-2) on the surface of endothelial cells.
Vegzelma is indicated for the treatment of six types of cancer: metastatic colorectal cancer; recurrent or metastatic non-squamous non-small cell lung cancer (nsNSCLC); recurrent glioblastoma; metastatic renal cell carcinoma; persistent, recurrent, or metastatic cervical cancer; and epithelial ovarian, fallopian tube, or primary peritoneal cancer.